Study conducted by Sociedade Brasileira de Oncologia Clínica (SBOC), Brazil
introduction Roughly 14.1 million new cases of cancer and 8.2 million deaths occurred worldwide in 2012. 1 New drugs and treatments have started to improve outcomes in high-income nations as well as in low-and middle-income countries. Many alternative therapies, some even called "miracle therapies," have risen in every part of the world and a few cancer hoaxes exist that are older than the discipline of medical oncology itself. However, rarely we have had the opportunity to observe and document the appearance and development of an alternative treatment in real time as we now do for phosphoethanolamine in Brazil.
As social media has become more widely available, unreliable and untruthful information can be broadcasted to an even wider audience. In Brazil, it was social media that made a case for phosphoethanolamine and took the country by storm. Phosphoethanolamine is a precursor of the biosynthesis of phospholipids in the cellular membrane and part of the cell signaling system either directly or via second messengers. A chemistry professor and his team in one of the campuses of the University of São Paulo have studied the drug in its synthetic version. Potential antineoplastic effects have been demonstrated in a few preclinical studies using cell lines [2] [3] [4] [5] and mice models; 6, 7 nonetheless, no appropriate safety studies have been carried out in humans. That has not kept the research team from manufacturing the substance in one of the chemistry laboratories at the university and distributing it to an increasing number of patients over the years. In 2015, after the university administration stopped this unsupported practice, patients who had been receiving the substance filed for court order to guarantee continued access to it.
In October 2015, one of the cases reached a Brazilian Federal Court judge, who ruled that patients could continue using phosphoethanolamine and that the university laboratory should not stop making it. Following this decision, additional lawsuits were brought forward. In the same month, a hearing in the National Congress demonstrated the commotion of patients who placed all their hope in the supposed drug and clamored for action. After this meeting, the Ministry of Health created and funded (to the tune of US$2.5 million) a task force to conduct preclinical studies and clinical trials to evaluate phosphoethanolamine as a cancer treatment.
The upheaval and pressure from groups of patients and family members have been so forceful and misguided that legislators have approved a path for the distribution of phosphoethanolamine even before adequate studies were done and evaluated by the Brazilian drug authority, Anvisa (Agência Nacional de Vigilância Sanitária, in portuguese), which in conjunction with the Ministry of Health and medical groups are now asking the president to veto the bill.
As there are no clinical data available on the use of phosphoethanolamine, we designed this survey of medical oncologists in Brazil not only to evaluate their experience with the substance, but also to assess their knowledge, opinion and attitudes on this unfolding story.
Method

Study design
This was an official study designed and carried out by the Brazilian Society of Clinical Oncology (SBOC). We designed a cross-sectional study and developed a survey, which was sent three times by e-mail and three times by text message in 3 to 5-day intervals to active MDs member of the SBOC. A questionnaire with closed-ended questions was applied. The main issues were: how many patients used phosphoethanolamine, how many wished to use it, if any side effects or benefits were seen in those who used it, what was the oncologist's opinion and what recommendation was given to the patient regarding phosphoethanolamine, how many studies the doctor had access to, what would be their position in relation to the distribution of phosphoethanolamine, what was their opinion on the conduct of clinical studies, and the degree of agreement with the opinion of the representatives of SBOC. Data collected between December 11 th and 18 th , 2015, included demographic information and the physicians' knowledge and opinions regarding the use of phosphoethanolamine in cancer treatment.
Statistical analysis
We used descriptive statistics to evaluate and present the data gathered.
Contingency tables were used to associate the sample characteristics (region where respondent practices, gender and field of practice) to the provided answers regarding phosphoethanolamine. Statistical significance between the variables was tested by Pearson's Chi-squared test.
Data was processed using statistical software PASW, version 18. In all statistical tests, a two-tailed level of 5% of significance (p<0.05) was considered.
A formal sample size computation was not performed because this was an exploratory cross-sectional study where the more responses we had, the more information we would gather about the physicians' experience with phosphoethanolamine. Therefore, we aimed to gather the maximum respondents among all current 1,072 active members of the SBOC.
results
Characteristics of the respondents
The survey was sent to all oncologists who were active members of the SBOC (1,072 doctors), of which 398 (37.1%) answered at least part of it. Among responders, 209 (52.5%) practice medicine in the Southeastern region, 67 (16.8%) in the Northeastern region, 71 (17.8%) in the Southern region, 34 (8.5%) in the Midwestern region and eight (2%) in the Northern region ( Figure 1 ). Nine doctors (2.3%) did not answer which region they were from. 104 (26.1%) of the individuals were men and 49 (12.3%) were women (61.6% of respondents did not answer this question).
As for the setting of practice, 170 (42.7%) oncologists perform their activities in both the public and private sectors, 163 (41%) work predominantly in the private sector and 64 (16.1%) predominantly in the public sector.
One hundred and fifteen (28.9%) oncologists had followed patients who had used or were using phosphoethanolamine, 93 of whom (80.9%) had up to five patients in this scenario. Among them, only 14 (12.2%) physicians observed any adverse events and four (3.5%) attributed some clinical benefit to the treatment. A total of 378 (95%) respondents stated that they had had patients who wished to use this substance.
As for the recommendation given to patients about the use of phosphoethanolamine, 198 (49.7%) oncologists did not recommend its use, 113 (28.4%) contraindicated it, 42 (10.6%) accepted its use as a complementary treatment as long as another prescribed treatment with an approved drug was maintained, and 15 (3.8%) accepted it depending on the circumstances.
Overall, 299 (75.1%) respondents had not read any scientific studies on phosphoethanolamine, 94 (23.6%) had read between one and five preclinical studies, four (1%) had read five to ten, and one (0.3%) individual answered that he or she had read more than ten studies.
One hundred and fifty four oncologists (38.7%) did not have any informed opinion regarding the drug, and of these, 112 (72.7%) thought it was likely to be well-tolerated. About a quarter of respondents (96, 24.1%) were not convinced of its efficacy despite considering that phosphoethanolamine is likely to be well-tolerated, 31 (7.8%) believed it to be not active and likely to have relevant adverse effects, and two (0.5%) considered it as likely to be an active drug.
As for patient access to phosphoethanolamine, 331 oncologists (83.2%) defended the position that it should only be provided to patients in the context of clinical trials, 26 (6.5%) that it could be considered off protocol, since there were no potentially approved treatments, and two (0.5%) said that it should be administered to any patient who asks for it. The others had either no informed opinion or did not answer.
When questioned if clinical trials probing phosphoethanolamine were a priority, 113 (28.4%) of the respondents agreed, whereas 197 (49.5%) shared the opinion that testing is necessary but not a priority. Approximately two thirds of oncologists (n=267; 67.1%) completely agreed with the position of the SBOC representatives in their public opinions, whereas 36 (6%) partly agreed. However, 86 oncologists (21.6%) had not seen the interviews nor read the articles in which the society stated its views that adequate clinical trials and evaluation by Anvisa should be undertaken before the substance becomes available to the public.
These results are detailed in Tables 1, 2 and 3 .
Chi-square tests No significant associations were observed between site of practice (private and/or public sector) and any of the answers to the survey. There was a significant association between region and access to phosphoethanolamine. Oncologists in the Southeast, South, and Midwest were more likely to have patients taking the substance compared with those in the North and Northeast.
discussion
There is clearly a need for more active therapeutic alternatives in cancer treatment and patients who have no further specific anticancer options may easily fall prey to the use of unproven therapies, especially when unconfirmed and poorly documented cases of response or symptomatic improvement appear in social media. In Brazil, phosphoethanolamine has quickly become the most commented--about alternative treatment.
In this study, we show that almost all oncologists in Brazil have had patients who voiced an interest in phosphoethanolamine and that a little less than one third of physicians in the country have treated individuals who used the substance. Potential clinical benefit, defined as clinical response or symptomatic improvement, was reported by a very small number of respondents (3.5%), as was the incidence of adverse events (reported by only 12.2% of oncologists).
The vast majority of oncologists do not think there is enough evidence for efficacy and do not recommend the drug, stating that it should be only used in the context of a clinical trial. Information about phosphoethanolamine is still very limited: 75% of the oncologists surveyed stated that they had never read any articles evaluating it and around one in five did not follow the interviews and mainstream media articles on the subject. This reflects the complete lack of scientific evidence about the clinical outcomes offered by phosphoethanolamine. The only available literature comprises preclinical studies with cell cultures and animal models where this substance has shown some antitumor activities in solid tumors, with the most recent one involving renal cell carcinoma. 5 A significant difference in the number of oncologists who followed patients using phosphoethanolamine in different regions of the country was observed. This is likely to be due to access to the molecule, which is produced in São Paulo, in the Southeastern region of Brazil, therefore making it more accessible in this area and in the adjacent South and Midwest of Brazil.
It is clear from the short time of it took us to enroll the planned sample in this study (only one week) that there is strong interest within the medical community; congressional hearings and the approved bill creating a path for the distribution of phosphoethanolamine also attest to the public's interest in this matter. SBOC and its members strongly believe, however, that adequate clinical trials are of paramount importance and absolutely needed before the substance can be considered in the treatment of patients with cancer. Furthermore, the uncontrolled distribution and use of phosphoethanolamine without proper evidence of its benefits and safety constitute a hazard to public health in Brazil.
Cancer patients often take alternative compounds. Systematic reviews have reported that 40 to 90% of patients with breast or gynecology cancers have taken alternative medicines while on oncology treatments or follow-up. 8 In this context, several supposedly "miracle drugs" such as herbs, vitamins, and fruit extracts, among others, have appeared in different countries. Commotion is expected within the society because cancer patients and their relatives are desperate to try anything that could cure or prolong their lives. Financial interests have led to many unproven compounds to be sold to cancer patients worldwide. One example is that of Sun Mushroom (Agaricus), which is native to Brazil and was used in the past for virtually all medical conditions, including cancer, due to its pre-clinical immunomodulatory effects. 9 Despite not being formally tested in clinical trials, it was used off-label in Brazil by many cancer patients. While the clinical effects of this mushroom have never been published, adverse events were observed in some patients, such as severe hepatic dysfunction. This example stresses how crucial it is to formally test new compounds in well-designed clinical trials.
This study has some limitations, the main one being a possible selection bias. Only active members of the SBOC were invited to answer the survey and 37.1% of them answered the questionnaire. However, given that this is the first survey about the experience with phosphoethanolamine and there are no clinical trials available studying the use of this substance, it represents the best available evidence for its use. Detailed information about tumor types and setting were not collected, which prevented us from evaluating the cases of responsive patients.
We expect that society, lawmakers, and the judicial system will reach the understanding that drug development is a scientific matter and redirect their efforts into improving and expediting our regulatory system for clinical trials and drug approval, speeding up the availability of truly promising drug candidates and proven medications to our patients.
conclusion
To our knowledge, this is the first survey to assess the opinion and experience of oncologists during the early stages of use of a supposed "miracle" alternative therapy. The results show that most oncologists in Brazil do not believe that synthetic phosphoethanolamine is active in the treatment of cancer, do not recommend its use without proper evaluation, and state that it should only be available to patients in the context of clinical trials.
resuMo Uma "milagrosa" droga contra o câncer na era da mídia social: uma pesquisa sobre a opinião e a experiência dos oncologistas brasileiros com a fosfoetanolamina Introdução: Alguns pacientes com diagnóstico de câncer utilizam terapias alternativas. Na era da internet, as informações podem se dissipar de forma rápida e abrangente, como foi o caso da fosfoetanolamina no Brasil, onde foi aclamada pela população como sendo a "cura para o câncer". Método: Trata-se de um estudo transversal desenvolvido pela Sociedade Brasileira de Oncologia Clínica (SBOC). Através de e-mail e SMS, enviou-se um questionário com perguntas objetivas para oncologistas membros ativos da SBOC. Os dados foram avaliados por meio de estatística descritiva. A significância estatística entre as variáveis foi testada pelo teste Qui-quadrado de Pearson (p<0,05 foi considerado significativo). Resultados: O questionário foi enviado para 1.072 oncologistas, tendo 398 (37,1%) respondido pelo menos parte dele. Cento e quinze (28,9%) tinham pacientes que fizeram uso da fosfoetanolamina. Desses, 14 (12,2%) observaram eventos adversos e quatro (3,5%) atribuíram benefício clínico para a substância. A maioria (n=331; 83,2%) acreditava que ela só deveria ser utilizada dentro de um ensaio clínico. A principal recomendação dada aos pacientes foi contra o seu uso (n=311; 78,1%). Oncologistas das regiões Sudeste, Sul e Centro-Oeste tiveram mais pacientes que tomaram a substância quando comparados com as regiões Norte e Nordeste. Conclusão: Este é o primeiro estudo que avalia a opinião dos oncologistas sobre essa terapia alternativa e sua experiência. A maioria dos oncologistas brasileiros não acredita que a fosfoetanolamina sintética seja ativa no tratamento do câncer, não recomendando seu uso sem avaliação adequada, e afirmam que a substância só deve estar disponível no contexto de ensaios clínicos.
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